PRKG1: A Potential Drug Target and Biomarker (G5592)

Target Name: PRKG1

NCBI ID: G5592

PRKG1

PRKG1: A Potential Drug Target and Biomarker

PRKG1 (cGK) is a protein that is expressed in human tissues and has been shown to play a role in various physiological processes in the body. One of the most promising aspects of PRKG1 is its potential as a drug target or biomarker. This article will discuss the research on PRKG1, its potential drug targeting properties, and its role as a biomarker in various diseases.

PRKG1 is a gene that encodes a protein known as cGK (cGK-1). The cGK protein is a member of the family of cytoskeletal proteins known as the alpha-actinin repeats (A-repeat) proteins. This family of proteins is characterized by the presence of a unique repeat sequence known as the alpha-actinin repeat. The alpha-actinin repeat is a transmembrane domain that is involved in various cellular processes, including cell signaling, cytoskeletal organization, and intracellular signaling.

One of the most promising aspects of PRKG1 is its potential as a drug target. PRKG1 has been shown to play a role in various physiological processes, including cell signaling, angiogenesis, and cancer progression. PRKG1 has also been shown to interact with various signaling pathways , including the TGF-β pathway. This suggests that PRKG1 may be a useful target for drugs that are designed to modulate TGF-β signaling.

In addition to its potential as a drug target, PRKG1 has also been shown to be a potential biomarker for various diseases. For example, PRKG1 has been shown to be elevated in the blood samples of patients with various types of cancer, including breast, lung , and ovarian cancer. This suggests that PRKG1 may be a useful biomarker for cancer diagnosis and treatment.

Another promising aspect of PRKG1 is its role in the regulation of cellular processes. For example, PRKG1 has been shown to play a role in the regulation of cell adhesion, cell migration, and the formation of tight junctions. These processes are important for various cellular functions, including tissue repair and regeneration, and may be targets for drugs that are designed to modulate these processes.

In conclusion, PRKG1 is a protein that has shown promise as a drug target and biomarker. Its unique alpha-actinin repeat and its involvement in various cellular processes make it a promising target for drugs that are designed to modulate signaling pathways. Further research is needed to fully understand the role of PRKG1 in various physiological processes and its potential as a drug target and biomarker.

Protein Name: Protein Kinase CGMP-dependent 1

Functions: Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle

The "PRKG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets